Brain‐targeted exosome‐mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti‐tumor effects in glioblastoma animal models

Bioengineering and Translational Medicine - Tập 8 Số 2 - 2023
Youngki Lee1, Minkyung Kim1, Junkyu Ha1, Minhyung Lee1
1Department of Bioengineering, College of Engineering, Hanyang University, Seoul, Korea

Tóm tắt

AbstractThe brain‐targeted delivery of therapeutic oligonucleotides has been investigated as a new treatment modality for various brain diseases, such as brain tumors. However, delivery efficiency into the brain has been limited due to the blood–brain barrier. In this research, brain‐targeted exosome‐mimetic cell membrane nanovesicles (CMNVs) were designed to enhance the delivery of therapeutic oligonucleotides into the brain. First, CMNVs were produced by extrusion with isolated C6 cell membrane fragments. Then, CMNVs were decorated with cholesterol‐linked T7 peptides as a targeting ligand by hydrophobic interaction, producing T7‐CMNV. T7‐CMNV was in aqueous solution maintained its nanoparticle size for over 21 days. The targeting and delivery effects of T7‐CMNVs were evaluated in an orthotopic glioblastoma animal model. 2′‐O‐metyl and cholesterol‐TEG modified anti‐microRNA‐21 oligonucleotides (AMO21c) were loaded into T7‐CMNVs, and biodistribution experiments indicated that T7‐CMNVs delivered AMO21c more efficiently into the brain than CMNVs, scrambled T7‐CMNVs, lipofectamine, and naked AMO21c after systemic administration. In addition, AMO21c down‐regulated miRNA‐21 (miR‐21) levels in glioblastoma tissue most efficiently in the T7‐CMNVs group. This enhanced suppression of miR‐21 resulted in the up‐regulation of PDCD4 and PTEN. Eventually, brain tumor size was reduced in the T7‐CMNVs group more efficiently than in the other control groups. With stability, low toxicity, and targeting efficiency, T7‐CMNVs may be useful to the development of oligonucleotide therapy for brain tumors.

Từ khóa


Tài liệu tham khảo

10.1517/13543780903052764

10.3390/cancers5041271

10.1089/104303400750038499

Hossain JA, 2020, Suicide gene therapy for the treatment of high‐grade glioma: past lessons, present trends, and future prospects, Neurooncol Adv, 2

10.1016/j.lfs.2021.119368

10.1038/nrd3179

10.1016/j.bbrc.2009.06.034

10.1007/s00401-009-0525-0

10.1016/j.toxrep.2020.11.001

10.1038/sj.onc.1210856

10.1158/0008-5472.CAN-07-1045

10.1038/s41568-019-0205-x

10.1016/j.jconrel.2019.11.009

10.1016/j.drudis.2019.10.005

10.1039/D1NR03455C

10.1016/j.brainresbull.2018.10.009

10.1016/j.biomaterials.2015.04.028

10.18520/cs/v112/i03/490-498

Alahari SK, 1996, Inhibition of expression of the multidrug resistance‐associated P‐glycoprotein of by phosphorothioate and 5′ cholesterol‐conjugated phosphorothioate antisense oligonucleotides, Mol Pharmacol, 50, 808

10.1016/j.jconrel.2016.02.007

10.1159/000313467

10.1016/j.jconrel.2021.08.021

10.1021/mp100185f

10.1021/acs.molpharmaceut.0c01119

10.1166/jbn.2019.2866

10.2147/IJN.S36111

10.1023/A:1014861900478

10.1021/ja1043177

10.1016/j.matdes.2020.108742

10.3892/mmr.2014.2914

Mastronardi L, 1999, Relationship between Ki‐67 labeling index and survival in high‐grade glioma patients treated after surgery with tamoxifen, J Neurosurg Sci, 43, 263

10.1002/(SICI)1097-0142(19960315)77:6<1161::AID-CNCR24>3.0.CO;2-Z

10.4161/cbt.8.19.9762

10.1007/s11060-009-9827-2

10.3390/ijms161025536

10.3390/pharmaceutics12100950

10.7150/ntno.57657

10.1016/j.jcis.2021.02.006

10.1002/adma.201602173

10.1016/j.jconrel.2021.07.004

Thông tin
Thông tin xuất bản

Bioengineering and Translational Medicine

Tập 8 Số 2

Thông tin tác giả